An Artificial MiRNA Against HPSE Suppresses Melanoma Invasion Properties, Correlating with a Down-regulation of Chemokines and MAPK Phosphorylation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Jun 22

PMID 22719918

Citations 30

Authors

Xiaoyan Liu

Hong Fang

Hongchao Chen

Xiaoling Jiang

Deren Fang

Yan Wang

Dingxian Zhu

Affiliations

Soon will be listed here.

Abstract

Ribonucleic acid interference (RNAi) based on microRNA (miRNA) context may provide an efficient and safe therapeutic knockdown effect and can be driven by ribonucleic acid polymerase II (RNAP II). In this study, we designed and synthesized miR155-based artificial miRNAs against heparanase (HPSE) constructed with BLOCK-iT™ Pol II miR RNAi Expression Vector Kit. The expression levels of HPSE declined significantly in both the mRNA and protein levels in HPSE-miRNA transfected melanoma cells that exhibited reduction of adhesion, migration, and invasion ability in vitro and in vivo. We also observed that HPSE miRNA could inhibit the expressions of chemokines of interleukin-8 (IL8) and chemokine (C-X-C motif) ligand 1 (CXCL1), at both the transcriptional and translational levels. Further study on its probable mechanism declared that down-regulation of IL8 and CXCL1 by HPSE-miRNA may be correlated with reduced growth-factor simulated mitogen-activated kinase (MAPK) phosphorylation including p38 MAPK, c-Jun N-terminal kinase (JNK) and extracellular-signal-regulated kinase (ERK) 1 and 2, which could be rescued by miRNA incompatible mutated HPSE cDNA. In conclusion, we demonstrated that artificial miRNAs against HPSE might serve as an alterative mean of therapy to low HPSE expression and to block the adhesion, invasion, and metastasis of melanoma cells. Furthermore, miRNA-based RNAi was also a powerful tool for gene function study.

Citing Articles

Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials.

Mayasin Y, Osinnikova M, Kharisova C, Kitaeva K, Filin I, Gorodilova A Cells. 2024; 13(22).

PMID: 39594665 PMC: 11592585. DOI: 10.3390/cells13221917.

Genetic Alchemy unveiled: MicroRNA-mediated gene therapy as the Artisan craft in the battlefront against hepatocellular carcinoma-a comprehensive chronicle of strategies and innovations.

Murshed A, Alnoud M, Ahmad S, Ullah Khan S, Alissa M, Alsuwat M Front Genet. 2024; 15:1356972.

PMID: 38915826 PMC: 11194743. DOI: 10.3389/fgene.2024.1356972.

Recent advancements in the diagnosis and treatment of acral melanoma.

Alhaskawi A, Hasan Abdullah Ezzi S, Dong Y, Zhou H, Wang Z, Lai J J Zhejiang Univ Sci B. 2024; 25(2):106-122.

PMID: 38303495 PMC: 10835211. DOI: 10.1631/jzus.B2300221.

Insights into the Molecular Mechanisms Mediating Extravasation in Brain Metastasis of Breast Cancer, Melanoma, and Lung Cancer.

Alsabbagh R, Ahmed M, Alqudah M, Hamoudi R, Harati R Cancers (Basel). 2023; 15(8).

PMID: 37190188 PMC: 10137309. DOI: 10.3390/cancers15082258.

The Role and Therapeutic Value of Syndecan-1 in Cancer Metastasis and Drug Resistance.

Guo S, Wu X, Lei T, Zhong R, Wang Y, Zhang L Front Cell Dev Biol. 2022; 9:784983.

PMID: 35118073 PMC: 8804279. DOI: 10.3389/fcell.2021.784983.

References

Timar J, Lapis K, Dudas J, Sebestyen A, Kopper L, Kovalszky I . Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol. 2002; 12(3):173-86. DOI: 10.1016/S1044-579X(02)00021-4. View

Zhang Y, Li L, Wang Y, Zhang J, Wei G, Sun Y . Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma. Biochem Biophys Res Commun. 2007; 358(1):124-9. DOI: 10.1016/j.bbrc.2007.04.068. View

Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, PECKER I . Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 2001; 61(12):4655-9. View

Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T . Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002; 12(9):735-9. DOI: 10.1016/s0960-9822(02)00809-6. View

Rasmussen M, Iversen L, Johansen C, Finnemann J, Olsen L, Kragballe K . IL-8 and p53 are inversely regulated through JNK, p38 and NF-kappaB p65 in HepG2 cells during an inflammatory response. Inflamm Res. 2008; 57(7):329-39. DOI: 10.1007/s00011-007-7220-1. View

Anderson E, Boese Q, Khvorova A, Karpilow J . Identifying siRNA-induced off-targets by microarray analysis. Methods Mol Biol. 2008; 442:45-63. DOI: 10.1007/978-1-59745-191-8_4. View

Tan F, Yin J . RNAi, a new therapeutic strategy against viral infection. Cell Res. 2004; 14(6):460-6. PMC: 7092015. DOI: 10.1038/sj.cr.7290248. View

Lee Y, Kim M, Han J, Yeom K, Lee S, Baek S . MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23(20):4051-60. PMC: 524334. DOI: 10.1038/sj.emboj.7600385. View

Zhang L, Sullivan P, Goodman J, Gunaratne P, Marchetti D . MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011; 71(3):645-54. PMC: 3078691. DOI: 10.1158/0008-5472.CAN-10-1910. View

10.

Sun B, Dong Q, Ye Q, Sun H, Jia H, Zhu X . Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008; 48(6):1834-42. DOI: 10.1002/hep.22531. View

11.

Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P . Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2009; 21(6):1302-1307. DOI: 10.1093/annonc/mdp524. View

12.

Ohtawa Y, Naomoto Y, Shirakawa Y, Takaoka M, Murata T, Sonoda R . The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach. Hum Pathol. 2006; 37(9):1145-52. DOI: 10.1016/j.humpath.2006.04.005. View

13.

Wurm S, Neumeier M, Weigert J, Wanninger J, Gerl M, Gindner A . Insulin induces monocytic CXCL8 secretion by the mitogenic signalling pathway. Cytokine. 2008; 44(1):185-90. DOI: 10.1016/j.cyto.2008.08.003. View

14.

Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger A . Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood. 2010; 115(12):2449-57. PMC: 2845901. DOI: 10.1182/blood-2009-07-234757. View

15.

Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J . Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer. 2001; 95(5):295-301. DOI: 10.1002/1097-0215(20010920)95:5<295::aid-ijc1051>3.0.co;2-a. View

16.

McBride J, Boudreau R, Harper S, Staber P, Monteys A, Martins I . Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008; 105(15):5868-73. PMC: 2311380. DOI: 10.1073/pnas.0801775105. View

17.

Barash U, Cohen-Kaplan V, Dowek I, Sanderson R, Ilan N, Vlodavsky I . Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010; 277(19):3890-903. PMC: 3000436. DOI: 10.1111/j.1742-4658.2010.07799.x. View

18.

Scherr M, Eder M . Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle. 2007; 6(4):444-9. DOI: 10.4161/cc.6.4.3807. View

19.

Yuan J, Wang X, Zhang Y, Hu X, Deng X, Fei J . shRNA transcribed by RNA Pol II promoter induce RNA interference in mammalian cell. Mol Biol Rep. 2006; 33(1):43-9. DOI: 10.1007/s11033-005-3965-1. View

20.

Krutzfeldt J, Rajewsky N, Braich R, Rajeev K, Tuschl T, Manoharan M . Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005; 438(7068):685-9. DOI: 10.1038/nature04303. View